studies

la/mBC - HR-positive - 2nd line (L2), entinostat plus exemestane vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsE2112, 2021 0.99 [0.81; 1.20] 0.99[0.81; 1.20]E2112, 202110%608NAnot evaluable progression or deaths (PFS)detailed resultsE2112, 2021 0.87 [0.67; 1.13] 0.87[0.67; 1.13]E2112, 202110%608NAnot evaluable objective responses (ORR)detailed resultsE2112, 2021 1.06 [0.53; 2.09] 1.06[0.53; 2.09]E2112, 202110%608NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-18 12:01 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 353,358,359 - treatments: 1374